HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis.

Abstract
One of the most promising new strategies for the development of efficacious cancer therapies relies on the targeted delivery of biopharmaceutical to the tumor environment by the use of selective and specific antibodies. The identification of accessible perivascular proteins selectively overexpressed in cancer tissue may facilitate the development of antibody-based biopharmaceutical administration. This approach is potentially highly selective and specific, combining the presence of tumor biomarkers readily accessible from the blood vessels and the high rate of angiogenesis characteristic of cancer tissues. We performed ex vivo perfusions of surgically resected human colon cancer using a reactive ester derivative of biotin, thus achieving a selective covalent modification of accessible proteins in vascular structures and stroma. After extraction and purification, biotinylated proteins were digested and the resulting peptides submitted to a comparative mass spectrometry-based proteomic analysis, revealing quantitative differences between normal and cancer colon. Sixty-seven of the total 367 proteins identified were found to be preferentially expressed at the tumor site. We generated human monoclonal antibodies against 2 potential tumor targets, NGAL and GW112, and we proved their selective expression in cancer colon and not or barely in healthy tissues. This article presents the first proteomic analysis of human colorectal cancer structures readily accessible from the tumor vasculature, revealing the overexpression of novel tumor antigens which may serve as selective targets for antibody-based imaging and therapeutic biomolecular strategies.
AuthorsPaolo Conrotto, Christoph Roesli, Jascha Rybak, Philippe Kischel, David Waltregny, Dario Neri, Vincent Castronovo
JournalInternational journal of cancer (Int J Cancer) Vol. 123 Issue 12 Pg. 2856-64 (Dec 15 2008) ISSN: 1097-0215 [Electronic] United States
PMID18798264 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Copyright(c) 2008 Wiley-Liss, Inc.
Chemical References
  • Acute-Phase Proteins
  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • LCN2 protein, human
  • Lipocalin-2
  • Lipocalins
  • OLFM4 protein, human
  • Proto-Oncogene Proteins
  • Granulocyte Colony-Stimulating Factor
Topics
  • Acute-Phase Proteins (antagonists & inhibitors, immunology)
  • Adult
  • Aged
  • Antibodies, Monoclonal (pharmacology)
  • Antigens, Neoplasm (isolation & purification)
  • Antineoplastic Agents (pharmacology)
  • Biotinylation (methods)
  • Breast Neoplasms (immunology)
  • Chromatography, High Pressure Liquid
  • Colonic Neoplasms (diagnosis, immunology, metabolism)
  • Female
  • Gene Expression Regulation, Neoplastic
  • Granulocyte Colony-Stimulating Factor (antagonists & inhibitors, immunology)
  • Humans
  • Immunohistochemistry
  • Lipocalin-2
  • Lipocalins (antagonists & inhibitors, immunology)
  • Male
  • Mass Spectrometry
  • Middle Aged
  • Polymerase Chain Reaction
  • Proteomics
  • Proto-Oncogene Proteins (antagonists & inhibitors, immunology)
  • Reproducibility of Results
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: